Dapagliflozin in Heart Failure: Cardiologist's Practical Perspective

Early Initiation of SGLT2 Inhibitors: Potential Window of Opportunity to Improve HF Outcomes

The first hospitalization for HF represents a critical window for therapeutic optimization. Emerging evidence suggests that initiating SGLT2 inhibitors during or shortly after hospitalization can improve outcomes without compromising safety. A 2025 meta-analysis including 2,320 patients hospitalized with acute HF demonstrated significantly lower all-cause mortality (OR 0.71; 95% CI 0.55–0.92) and HF rehospitalization (OR 0.73; 95% CI 0.57–0.94) with early SGLT2i initiation. ⁴ Complementing these findings, the TIDY-HF registry (n=518) showed that initiating therapy with an SGLT2i facilitated greater uptake of quadruple GDMT at 6 months (81.5% vs 61.2%; p=0.0001), along with improvements in cardiac and renal outcomes among HFrEF patients. ⁵

Dapagliflozin Across the Heart Failure Continuum: What Current Evidence Tells Us

Effect of Dapagliflozin in HFrEF: The landmark DAPA-HF trial established dapagliflozin as a foundational therapy in HFrEF. Among 4,744 patients with symptomatic HFrEF (LVEF ≤40%), dapagliflozin 10 mg once daily, administered over a median follow-up of 18.2 months, reduced the relative risk of worsening HF or cardiovascular death by 26% compared with placebo (16.3% vs 21.2%; HR 0.74; 95% CI 0.65–0.85; p<0.001). ⁶

Dapagliflozin also reduced the relative risk of worsening HF events, including HF hospitalization or urgent HF visits, by 30% (HR 0.70; 95% CI 0.59–0.83) and lowered the relative risk of first HF hospitalization by approximately 30% (9.7% vs 13.4%) Importantly, benefits were consistent irrespective of diabetes status, reinforcing dapagliflozin's role as a core component of contemporary HFrEF management. ⁶

Dapagliflozin in HFmrEF & HFpEF: The benefits of dapagliflozin extend beyond HFrEF to patients with HFmrEF and HFpEF, populations with historically limited treatment options. In the landmark DELIVER trial, involving 6,263 patients with LVEF >40%, dapagliflozin 10 mg once daily, administered over a median follow-up of 2.3 years, reduced the relative risk of worsening HF or cardiovascular death by 18% compared with placebo (16.4% vs 19.5%; HR 0.82; 95% CI 0.73–0.92; p<0.001). ⁷

Again the benefits were consistent across the ejection fraction spectrum and irrespective of diabetes status, establishing dapagliflozin as one of the few therapies with proven efficacy across nearly the entire HF continuum.

Dapagliflozin in Acute Heart Failure: Acute HF hospitalization represents a critical opportunity to initiate disease-modifying therapy. In the DICTATE-AHF trial, dapagliflozin 10 mg once daily, initiated within 24 hours of presentation in 240 patients hospitalized with acute decompensated HF and type 2 diabetes, was associated with enhanced natriuresis, lower cumulative loop diuretic requirements (560 mg vs 800 mg furosemide equivalents; p=0.006), and earlier hospital discharge without an increase in adverse events. ⁸

In the DAPA-MI trial, dapagliflozin 10 mg once daily was evaluated in 4,017 patients with recent myocardial infarction and impaired left ventricular systolic function and/or Q-wave myocardial infarction. Over a median follow-up of 11.6 months, dapagliflozin significantly improved the primary hierarchical cardiometabolic outcome compared with placebo (win ratio 1.34; 95% CI 1.20–1.50; p<0.001), driven largely by reductions in new-onset diabetes and weight loss. ⁹

Applying Dapagliflozin: Practical Considerations in Cardiology Practice

As the evidence supporting dapagliflozin continues to strengthen and expand, the clinical question has shifted from whether to prescribe it to how early it should be integrated into HF management. Patients with symptomatic HF, recent HF hospitalization, concomitant CKD (particularly those with an eGFR ≥25 mL/min/1.73 m²), persistent congestion, or a high risk of recurrent events are likely to derive substantial benefit from early therapy. ³ Increasingly, hospitalization is being viewed as a window of opportunistic intervention to initiate dapagliflozin in heart failure, rather than deferring treatment until outpatient follow-up. ⁴

From a practical standpoint, dapagliflozin is easy to incorporate into contemporary GDMT owing to its fixed once-daily dosing, lack of titration requirements in most cases, and minimal impact on blood pressure. It can be initiated alongside ARNI/ACEI/ARB, beta-blockers, and MRAs, facilitating early establishment of the four foundational GDMT pillars of HF therapy. ³ Importantly, mild-to-moderate renal impairment should not be viewed as a barrier to treatment, as dapagliflozin has consistently demonstrated cardiorenal benefits across a broad range of patients. ¹⁰ For many cardiologists today, the focus is no longer on reserving dapagliflozin for advanced HF, but on identifying the earliest appropriate opportunity to initiate therapy and improve long-term outcomes, when appropriately indicated.

Dapagliflozin Beyond HHF Endpoints: Emerging Benefits Shaping Long-term Outcomes

The clinical value of dapagliflozin extends beyond reducing HF hospitalization. Dapagliflozin has also been associated with favorable reverse ventricular remodeling, including improvements in left ventricular structure and function, which may contribute to sustained cardiovascular benefit. ¹¹ Importantly, patients consistently report improvements in symptoms, functional capacity, and health-related quality of life. ¹² Emerging data further suggest a potential reduction in atrial and ventricular arrhythmias, highlighting a possible role in modifying the arrhythmic substrate in HF. ¹³

Dapagliflozin in Cardiomyopathy: Early Signals of Promise

Beyond established HF indications, emerging research suggests that dapagliflozin may have a role in diverse cardiomyopathy phenotypes. Experimental and clinical studies have demonstrated favorable effects on myocardial energetics, inflammation, fibrosis, and oxidative stress, key drivers of disease progression in both ischemic and non-ischemic cardiomyopathies. ^14-16 Dapagliflozin has also been associated with reverse ventricular remodeling, improved left ventricular function, and attenuation of adverse post-infarction remodeling. ^{15, 16} These findings suggest that its therapeutic potential may extend beyond conventional HF management into broader cardiomyopathy care. More research is needed in this direction.

Practice Pearl for Clinicians

Contemporary evidence suggests dapagliflozin as a foundational therapy across the HF spectrum, from HFrEF to HFpEF, with benefits extending beyond HF hospitalization reduction to cardiorenal protection, reverse cardiac remodeling, and improved quality of life.

Based on recent evidence, early initiation of SGLT2i, including Dapagliflozin, particularly during or soon after HF hospitalization, is emerging as a key strategy to optimize HF outcomes, when appropriately indicated.

Abbreviations: ACEI: angiotensin-converting enzyme inhibitor; AHF: acute heart failure; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor-neprilysin inhibitor; CKD: chronic kidney disease; CI: confidence interval; CV: cardiovascular; EF: ejection fraction; GDMT: guideline-directed medical therapy; HF: heart failure; HFmrEF: heart failure with mildly reduced ejection fraction; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; HR: hazard ratio; LVEF: left ventricular ejection fraction; MI: myocardial infarction; MRA: mineralocorticoid receptor antagonist; OR: odds ratio; SGLT2: sodium-glucose cotransporter-2; SGLT2i: sodium-glucose cotransporter-2 inhibitor.